

技術分析



分析師

大中華區研究團隊

research-hk@uobkh.com

譚文漢，特許財務分析師

munhon.tham@uobkh.com

+852 2236 6799

信達生物 (1801 HK)

最後價格：港幣 96.15 元
 支撐位：港幣 93.10 元/港幣 91.75 元
 阻力位：港幣 105.60 元/港幣 112.70 元

技術分析：

价格行为成功企稳于阻力转支撑区域上方，验证了结构性极性转换的顺畅完成，并将这一新转换的结构性锚点确立为有效需求地基。稳守在该锚点之上的表现指向潜在更低点的构建，确保了整体多头序列的完整性并消解了短线下行风险。技术动能进一步印证了这一建设性格局：RSI 指标正朝中性 50 中轴线方向勾头向上，信号显示抛压正在减弱且动能处于早期复苏阶段。只要低级别价格行为稳稳守住这一核心支撑锚点，最小阻力路径将高度倾斜于展开向更高拓展目标的持续反弹。

平均時限：約兩週。



翰森製藥 (3692 HK)

最後價格：港幣 34.34 元
 支撐位：港幣 32.28 元/港幣 30.76 元
 阻力位：港幣 37.16 元/港幣 40.12 元

技術分析：

价格行为成功企稳于缺口支撑区域上方，重新将缺口下沿确立为核心需求锚点。RSI 指标已转向看涨区域并呈上行斜率，信号显示趋势运行速度正在加速且买方控制力重新确立。只要价格稳稳守住这一缺口支撑，最小阻力路径将高度倾斜于维持向上推进，驱动价格向更高的核心拓展目标展开持续主升行情。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."